Mesoblast Seeks New Partner In Chronic Heart Failure, To Replace Teva
The surprise parting of ways between Mesoblast Ltd. and Teva Pharmaceutical Industries Ltd. leaves the Australian group seeking a new partner to pursue ongoing Phase III trials and subsequent commercialization for chronic heart failure product MPC-150-IM.
You may also be interested in...
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.